C12N 2740/10034
Use of virus or viral component as vaccine
Official title: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2740/10034 (Use of virus or viral component as vaccine) appears on 26 US grants and 42 published applications in this corpus.
Search patents in C12N- Granted patents
- 26
- Published applications
- 42
- Assignees
- 34
- Inventors
- 75
- Latest grant
- 19 Aug 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1999 | 1 | 0 |
| 2000 | 0 | 0 |
| 2001 | 1 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 1 |
| 2004 | 0 | 0 |
| 2005 | 0 | 1 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 1 | 1 |
| 2010 | 0 | 2 |
| 2011 | 0 | 1 |
| 2012 | 1 | 1 |
| 2013 | 1 | 1 |
| 2014 | 1 | 1 |
| 2015 | 0 | 3 |
| 2016 | 0 | 1 |
| 2017 | 2 | 3 |
| 2018 | 3 | 1 |
| 2019 | 2 | 4 |
| 2020 | 1 | 2 |
| 2021 | 3 | 3 |
| 2022 | 1 | 4 |
| 2023 | 1 | 1 |
| 2024 | 3 | 3 |
| 2025 | 4 | 6 |
| 2026 | 0 | 2 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Therapy for treating cancer with an intratumoral or intravenous administration of a recombinant MVA encoding 4-1BBL (CD137L) and/or CD40L19 Aug 2025US 12,390,515 B2Bavarian Nordic A/S
- Nucleic acids encoding human endogenous retrovirus K (HERV-k) envelope proteins containing modified immunosuppressive domains (ISD) and uses thereof19 Aug 2025US 12,390,522 B2Inprother Aps
- Virus vector production15 Jul 2025US 12,359,217 B2Fondazione Telethon Ets
- Vaccine for use in the prophylaxis and/or treatment of a disease1 Apr 2025US 12,263,214 B2Inprother Aps
- Methods of making and using universal centralized influenza vaccine genes20 Aug 2024US 12,064,478 B2NUtech Ventures
- Improved expression of surface-displayed antigens1 Oct 2026US 2026/0295030 A1Inprother Aps
- Nucleic acids encoding human endogenous retrovirus k (herv-k) envelope proteins containing modified immunosuppressive domains (isd) and uses thereof19 Mar 2026US 2026/0077031 A1Inprother Aps
- Virus vector production11 Dec 2025US 2025/0376696 A1Fondazione Telethon
- Human t cell receptors specific for antigenic peptides derived from mitogen-activated protein kinase 8 interacting protein 2 (mapk8ip2), epstein-barr virus or human endogenous retrovirus, and uses thereof21 Aug 2025US 2025/0262242 A1ImmunoSCAPE Pte. Ltd.
- Vaccine for use in the prophylaxis and/or treatment of a disease12 Jun 2025US 2025/0186579 A1Inprother Aps
Most cited
By later US patents
- Feline vaccines containing Chlamydia psittaci and method for making the same10US 5,972,350 ABaker Aktiengesellschaft · 1999
- CMV glycoproteins and recombinant vectors10US 9,541,553 B2Oregon Health & Science University · 2017
- CMV glycoproteins and recombinant vectors9US 10,101,329 B2Oregon Health & Science University · 2018
- Process for making an adjuvanted vaccine comprising host albumin8US 7,482,020 B22009
- Vaccine for use in the prophylaxis and/or treatment of a disease7US 11,351,247 B2Inprother Aps · 2022